Head to Head Contrast: uniQure (NASDAQ:QURE) and Annexon (NASDAQ:ANNX)

Annexon (NASDAQ:ANNX) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, institutional ownership, dividends, valuation and earnings.

Valuation and Earnings

This table compares Annexon and uniQure”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69 million	($1.36)	-4.21
uniQure	$16.10 million	82.89	-$198.97 million	($3.45)	-6.13

uniQure has higher revenue and earnings than Annexon. uniQure is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Annexon and uniQure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-101.33%	-76.96%
uniQure	-1,236.00%	-174.03%	-27.41%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Annexon and uniQure, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	1	1	5	0	2.57
uniQure	1	6	10	0	2.53

Annexon presently has a consensus price target of $17.00, indicating a potential upside of 197.20%. uniQure has a consensus price target of $44.50, indicating a potential upside of 110.30%. Given Annexon’s stronger consensus rating and higher possible upside, equities analysts plainly believe Annexon is more favorable than uniQure.

Risk & Volatility

Annexon has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, uniQure has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.

Insider & Institutional Ownership

78.8% of uniQure shares are held by institutional investors. 12.7% of Annexon shares are held by insiders. Comparatively, 4.8% of uniQure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Annexon beats uniQure on 8 of the 13 factors compared between the two stocks.

About Annexon

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.